domingo, 27 de mayo de 2012

Convergence and coevolution of hepatitis B virus ... [Nat Commun. 2012] - PubMed - NCBI

Convergence and coevolution of hepatitis B virus ... [Nat Commun. 2012] - PubMed - NCBI

Nat Commun. 2012 Apr 17;3:789. doi: 10.1038/ncomms1794.

Convergence and coevolution of hepatitis B virus drug resistance.


Molecular Epidemiology and Bioinformatics Laboratory, Division of Viral Hepatitis, Center for Disease Control and Prevention, Atlanta 30329, Georgia, USA.


Treatment with lamivudine of patients infected with hepatitis B virus (HBV) results in a high rate of drug resistance, which is primarily associated with the rtM204I/V substitution in the HBV reverse transcriptase domain. Here we show that the rtM204I/V substitution, although essential, is insufficient for establishing resistance against lamivudine. The analysis of 639 HBV whole-genome sequences obtained from 11 patients shows that rtM204I/V is independently acquired by more than one intra-host HBV variant, indicating the convergent nature of lamivudine resistance. The differential capacity of HBV variants to develop drug resistance suggests that fitness effects of drug-resistance mutations depend on the genetic structure of the HBV genome. An analysis of Bayesian networks that connect rtM204I/V to many sites of HBV proteins confirms that lamivudine resistance is a complex trait encoded by the entire HBV genome rather than by a single mutation. These findings have implications for public health and offer a more general framework for understanding drug resistance.

[PubMed - in process]
Free PMC Article

No hay comentarios:

Publicar un comentario